Indication
In a combination regimen with ivacaftor 150 mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.

Medicine details

Medicine name:
tezacaftor-ivacaftor (Symkevi)
SMC ID:
SMC2183
Pharmaceutical company
Vertex Pharmaceuticals Ltd
BNF chapter
Submission type
Full
Status
Publication due date:
12 August 2019
SMC meeting date:
02 July 2019
Patient group submission deadline:
06 May 2019